Sumitomo Pharma (4506) Q3 2026 earnings summary

Executive summary

• Q3 FY2025 revenue reached ¥347.7 billion, up 18.6% year-over-year, driven by strong North American product sales and milestone revenue from ORGOVYX®.

• Core operating profit surged 408.5% to ¥109.4 billion, reflecting gains from a partial transfer of the Asian business and lower R&D expenses.

• Net profit attributable to owners increased 407.5% to ¥107.7 billion, supported by gains from the partial transfer of the Asian business.

• Q3 results exceeded expectations, driven by strong product performance, favorable FX, and inventory buildup.

• Revenue, core operating profit, and net profit all saw significant year-over-year increases, with North America as the primary growth driver.

Financial highlights

• Revenue increased by ¥54.6 billion year-over-year, with North America contributing significantly.

• Major North American products (ORGOVYX®, Myfembree, GEMTESA®) generated ¥257.5 billion, up ¥78.1 billion year-over-year.

• ORGOVYX® sales nearly doubled year-over-year to ¥115.6 billion; GEMTESA® up 67.5% to ¥72.3 billion.

• SG&A and R&D expenses decreased by ¥8.0 billion and ¥7.5 billion, respectively, due to business structure improvements.

• Operating profit rose to ¥109.8 billion from ¥13.2 billion, mainly due to a ¥49.0 billion gain on the Asian business transfer.

Outlook and guidance

• Full-year forecast remains unchanged despite Q3 outperformance, as Q4 is expected to be weaker due to insurance resets and expense concentration.

• FY2025 revenue forecast is ¥429.0 billion, with core operating profit projected at ¥97.0 billion.

• Regulatory approval for iPS cell-derived Parkinson's therapy in Japan targeted for FY2025.